Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "from using higher doses of dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "for Covid-19 patients dexamethasone" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label "to perform MD simulations to analyze dexamethasone ( Dex ) stability at 50 ns" provenance.
- OBJECT label ""to dexamethasone s ability to improve cortical function"" provenance.
- OBJECT label ""to dexamethasone s ability to improve cortical function"" provenance.
- OBJECT label ""to dexamethasone s ability to improve cortical function"" provenance.
- OBJECT label ""to dexamethasone s ability to improve cortical function"" provenance.
- OBJECT label ""to dexamethasone s ability to improve cortical function"" provenance.
- OBJECT label ""to dexamethasone s ability to improve cortical function"" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.